


**CLAIMS:**

1. The use, for the manufacture of a medicament for treating or preventing a disease associated with deposition of A $\beta$  in the brain, of a compound of Formula I



5

wherein each R<sup>1</sup> is independently H, C<sub>1-6</sub>alkyl or C<sub>3-6</sub>cycloalkyl;

each R<sup>2</sup> is independently H or C<sub>1-6</sub>alkyl, or the two R<sup>2</sup> groups together complete a C<sub>3-6</sub>cycloalkyl group;

R<sup>3</sup> represents a hydrocarbon group of up to 10 carbon atoms optionally bearing up to 2 substituents selected from halogen, CN, CF<sub>3</sub>, OCF<sub>3</sub>, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkylthio, CO<sub>2</sub>H, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkylcarbonyl and C<sub>1-4</sub>alkylcarbonyloxy; or R<sup>3</sup> represents a heteroaryl group of 5 or 6 ring atoms which is optionally benzo-fused, optionally bearing up to 2 substituents selected from C<sub>1-4</sub>alkyl, halogen, CN, CF<sub>3</sub>, OCF<sub>3</sub>, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkylthio, CO<sub>2</sub>H, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkylcarbonyl and C<sub>1-4</sub>alkylcarbonyloxy;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> independently represent H, halogen, CN, CF<sub>3</sub>, OCF<sub>3</sub>, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkylthio, CO<sub>2</sub>H, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkylcarbonyl, C<sub>1-4</sub>alkylcarbonyloxy or hydrocarbon of up to 7 carbon atoms optionally bearing a substituent selected from halogen, CN, CF<sub>3</sub>, OCF<sub>3</sub>, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkylthio, CO<sub>2</sub>H, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkylcarbonyl and C<sub>1-4</sub>alkylcarbonyloxy;

R<sup>7</sup> represents a hydrocarbon group of up to 10 carbon atoms optionally bearing up to 2 substituents selected from halogen, CN, CF<sub>3</sub>, OCF<sub>3</sub>, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkylthio, CO<sub>2</sub>H, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkylcarbonyl and C<sub>1-4</sub>alkylcarbonyloxy;


X represents O or S;

Y represents a bond, CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>O; and  
Z represents CO<sub>2</sub>H or tetrazol-5-yl;  
or a pharmaceutically acceptable salt thereof.

- 5           2.       Use according to claim 1 wherein said disease is selected from Alzheimer's disease, cerebral amyloid angiopathy, HCHWA-D, multi-infarct dementia, dementia puglistica and Down syndrome.
- 10           3.       Use, for the manufacture of a medicament for treating, preventing or delaying the onset of dementia associated with Alzheimer's disease, cerebral amyloid angiopathy, HCHWA-D, multi-infarct dementia, dementia pugilistica or Down syndrome, of a compound of Formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof.
- 15           4.       Use, for the manufacture of a medicament for retarding, arresting or preventing the accumulation of A $\beta$  in the brain, of a compound of Formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof.
- 20           5.       Use according to any previous claim in which the medicament is for administration to a patient suffering from mild cognitive impairment or age related cognitive decline.
6.       Use according to any previous claim wherein X is S.
- 25           7.       Use according to any previous claim wherein Y is CH<sub>2</sub>.
8.       Use according to any previous claim wherein Z is CO<sub>2</sub>H.
- 30           9.       Use according to any previous claim wherein R<sup>3</sup> in formula I is selected from alkyl, cycloalkyl, alkyl-substituted phenyl and chloro-substituted phenyl.

10. Use according to any previous claim wherein  $R^7$  in formula I is selected from alkyl, cycloalkyl or alkenyl of up to 6 carbon atoms, or optionally substituted phenyl.


5 11. Use according to claim 1 of a compound according to formula II:



wherein  $R^{1a}$  represents  $C_{1-6}$ alkyl or  $C_{3-6}$ cycloalkyl, and  $R^2$ - $R^7$ , X, Y and Z are as defined in claim 1;


10 or a pharmaceutically acceptable salt thereof.

12. Use according to claim 1 of a compound according to formula III:




15 wherein n is 1 or 2 and  $R^1$ - $R^6$ , X, Y and Z are as defined in claim 1;  
or a pharmaceutically acceptable salt thereof.

13. A compound of formula II



wherein  $R^{1a}$  represents  $C_{1-6}$ alkyl or  $C_{3-6}$ cycloalkyl, and  $R^2$ - $R^7$ , X, Y and Z are as  
 5 defined in claim 1;  
 or a pharmaceutically acceptable salt thereof.

14. A compound of formula III:



10

wherein n is 1 or 2 and  $R^1$ - $R^6$ , X, Y and Z are as defined in claim 1;  
 or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising, in a pharmaceutically  
 15 acceptable carrier, a compound of formula II or formula III, or a pharmaceutically  
 acceptable salt thereof.